Literature DB >> 19424628

Clinical significance of the gene expression profile in residual tumor cells after neoadjuvant chemo-radiotherapy for esophageal cancer.

Koji Tanaka1, Kohhei Otake, Yasuhiko Mohri, Masaki Ohi, Takeshi Yokoe, Yuji Toiyama, Chikao Miki, Hitoshi Tonouchi, Masato Kusunoki.   

Abstract

Recurrence after neoadjuvant chemo-radiotherapy (CRT) followed by surgery is high in patients with esophageal cancer. No standard second line therapy is currently available for patients with recurrence. This study aimed to evaluate the expression of chemo-radiosensitive genes after neoadjuvant CRT in residual tumor cells. Thirteen patients with esophageal squamous cell carcinoma underwent 5-fluorouracil (5-FU) and cisplatin (CDDP) based CRT followed by surgery. Total RNA was successfully obtained from 6 formalin-fixed paraffin-embedded (FFPE) specimens using proteinase K digestion and phenol chloroform extraction. TS and DPD as the 5-FU pathway gene, ERCC1 as the CDDP pathway gene, and EGFR, VEGF, HIF1a as radioresistant genes were measured using real-time reverse transcription polymerase chain reaction; comparing the mRNA level of each gene in pre-CRT biopsy with that in post-CRT FFPE specimens. Five patients had less than one-third residual tumor cells in resected specimens histopathologically; eight had more than two-thirds residual tumor cells. There were significant increases in TS (p=0.02) and DPD (p=0.01) levels in residual tumor cells after CRT. Significant decreases in ERCC1 (p=0.03), EGFR (p=0.01), VEGF (p=0.003) and HIF1a (p=0.003) levels were observed. 5-FU and CDDP based CRT up-regulated 5-FU pathway genes and down-regulated CDDP pathway and radioresistant genes. The expression of chemo-radiosensitive genes was significantly changed in residual tumor cells after CRT. Gene expression analysis of residual tumor cells in FFPE specimens may be useful when selecting a second line chemotherapy regimen for recurrent esophageal cancer after CRT.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19424628     DOI: 10.3892/or_00000379

Source DB:  PubMed          Journal:  Oncol Rep        ISSN: 1021-335X            Impact factor:   3.906


  3 in total

1.  HsMAD2 mRNA expression may be a predictor of sensitivity to paclitaxel and survival in neuroblastoma.

Authors:  Kohei Otake; Keiichi Uchida; Kouji Tanaka; Yuhki Koike; Mikihiro Inoue; Kohei Matsushita; Motoko Ueeda; Kiyoshi Hashimoto; Takahito Kitajima; Yoshihiro Komada; Masato Kusunoki
Journal:  Pediatr Surg Int       Date:  2011-02       Impact factor: 1.827

2.  Thymidylate synthetase and dihydropyrimidine dehydrogenase mRNA levels in esophageal cancer.

Authors:  Masahiro Kimura; Yoshiyuki Kuwabara; Akira Mitsui; Hideyuki Ishiguro; Nobuyoshi Sugito; Tatsuya Tanaka; Midori Shiozaki; Yasuhiro Naganawa; Hiromitsu Takeyama
Journal:  Oncol Lett       Date:  2010-12-16       Impact factor: 2.967

Review 3.  Molecular mechanisms associated with chemoresistance in esophageal cancer.

Authors:  Matheus Lohan-Codeço; Maria Luísa Barambo-Wagner; Luiz Eurico Nasciutti; Luis Felipe Ribeiro Pinto; Nathalia Meireles Da Costa; Antonio Palumbo
Journal:  Cell Mol Life Sci       Date:  2022-02-03       Impact factor: 9.261

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.